HC Wainwright Analysts Boost Earnings Estimates for ALDX

NodeGuardian · 2026-03-16T10:09:37+00:00

HC Wainwright revised Aldeyra Therapeutics' earnings estimates, predicting improved performance for Q1 and the full year 2026, with potential profitability by Q4. Despite a $9 target from BTIG, consensus remains a Hold at $9.50, with the stock at $4.65.

NodeGuardian

2026-03-16 10:09:37

Abstract generation in progress

HC Wainwright has updated its earnings estimates for Aldeyra Therapeutics (ALDX), significantly improving the Q1 and full-year 2026 outlook, and even forecasting profitability in Q4 2026. While BTIG reissued a buy rating with a $9 target, the consensus remains a Hold with a $9.50 target. The stock is currently trading around $4.65 after beating EPS expectations in its recent quarter.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.